Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.49 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052765 | 0.89 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL5052771 | 0.89 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL27552226 | 0.86 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL30514301 | 0.84 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL425154 | 0.83 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL42133 | 0.83 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL12658269 | 0.83 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL6002015 | 0.83 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL19666777 | 0.83 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL2168188 | 0.82 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636374-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12616744-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PFIZER INC. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4715054-A1 | APTAMERS, APTAMER-BASED SENSORS AND METHODS FOR DETECTING NEUROFILAMENT LIGHT | Forschungszentrum Jülich GmbH (DE) | 2026-03-25 | — | — | EP | disclosed |
| US-20260061043-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS, KITS COMPRISING THE SAME AND USES THEREOF | PFIZER (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260048112-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS, KITS COMPRISING THE SAME AND USES THEREOF | PFIZER INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260027195-A1 | IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINES | PFIZER (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260014241-A1 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PFIZER (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250381259-A1 | Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof | PFIZER (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4661911-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF | Pfizer Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4649956-A2 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS, KITS COMPRISING THE SAME AND USES THEREOF | Pfizer Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20060263336-A1 | Cell targeting methods and compositions | CAPLAN ARNOLD I | 2006-11-23 | — | — | US | disclosed |
| WO-2006102395-A2 | DELIVERY SYSTEMS AND METHODS FOR DIAGNOSING AND TREATING CARDIOVASCULAR DISEASES | MEDSTAR HEALTH INC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060019408-A1 | Optical biosensors and methods of use thereof | CARNEGIE MELLON UNIVERSITY | 2006-01-26 | — | — | US | disclosed |
| EP-1558086-A2 | CELL TARGETING METHODS AND COMPOSITIONS | Case Western Reserve University (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004084950-A2 | CELL TARGETING METHODS AND COMPOSITIONS | CASE WESTERN RESERVE UNIVERSITY (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004025268-A2 | OPTICAL BIOSENSORS AND METHODS OF USE THEREOF | CARNEGIE MELLON UNIVERSITY (US) | 2004-03-25 | — | — | WO | disclosed |
| US-20040048370-A1 | Cell targeting methods and compositions | CASE WESTERN RESERVE UNIVERSITY | 2004-03-11 | — | — | US | disclosed |
| WO-2003106640-A2 | CELL TARGETING METHODS AND COMPOSITIONS | CASE WESTERN RESERVE UNIVERSITY (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030054408-A1 | Methods and systems for identifying proteins | RAVI RAMAMOORTHI (US) | 2003-03-20 | — | — | US | disclosed |
| WO-2002086081-A2 | METHODS AND SYSTEMS FOR IDENTIFYING PROTEINS | CARNEGIE MELLON UNIVERSITY (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048112-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS, KITS COMPRISING THE SAME AND USES THEREOF | IL17A, NEU3, SIGLEC9 | SLC28A1 3126/4885SLC28A2 3050/4885SLC29A1 2181/4885 |
| US-20250381259-A1 | Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof | CD44, CD47, FUT5 | SLC28A1 1876/4885SLC28A2 1681/4885SLC29A1 1922/4885 |
| US-20260027195-A1 | IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINES | IL17A, CD14, SPOUT1 | SLC28A1 1210/4885SLC28A2 1469/4885SLC29A1 1112/4885 |
| US-12616744-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PSEN1, CD44, CD47 | SLC28A1 2596/4885SLC28A2 2626/4885SLC29A1 1796/4885 |
| US-20260014241-A1 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | SIGLEC9, CMBL, CHI3L2 | SLC28A1 2144/4885SLC28A2 1188/4885SLC29A1 1298/4885 |
| US-12636374-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | CSGALNACT1, LY96, C5AR2 | SLC28A1 2949/4885SLC28A2 1392/4885SLC29A1 2742/4885 |
| US-20260061043-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS, KITS COMPRISING THE SAME AND USES THEREOF | IL17A, SIGLEC7, PSPH | SLC28A1 1942/4885SLC28A2 2183/4885SLC29A1 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.